Intercept Pharmaceuticals, Inc. (ICPT) Financial Analysis & Valuation | Quarter Chart
Intercept Pharmaceuticals, Inc. (ICPT)
ICPTPrice: $19
Fair Value: 🔒
🔒score
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of... more
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commerc... more
Description
Shares
| Market Cap | $794.69M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Jerome B. Durso |
| IPO Date | 2012-10-11 | CAGR | — |
| Employees | 341 | Website | www.interceptpharma.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.05% | Total Yield | 0.05% |
ICPT chart loading...
Fundamentals
Technicals
| Enterprise Value | $895.94M | P/E Ratio | -17.43 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 2.78 | P/B Ratio | 6.9 |
| P/CF Ratio | -24 | P/FCF Ratio | -29.06 |
| EPS | $-1.09 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -3.83% | Gross Margin | 1% |
| Operating Margin | -0.24% | Profit Margin | 0.4% |
| ROE | -2.53% | ROA | 0.21% |
| ROCE | -0.21% | Current Ratio | 2.35 |
| Quick Ratio | 2.32 | Cash Ratio | 0.22 |
| Debt/Equity | 3.57 | Interest Coverage | -3.19 |
| Altman Z Score | -5.01 | Piotroski Score | 3 |